$ICAD
ICAD INC

2020 Q2 Form 10-Q Financial Statement

#000119312520139218 Filed on May 11, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2020 Q1 2019 Q4
Revenue $5.570M $6.551M $9.381M
YoY Change -24.0% -3.28% 34.9%
Cost Of Revenue $1.210M $2.041M $2.220M
YoY Change -24.52% 36.89% 44.16%
Gross Profit $4.360M $4.510M $7.165M
YoY Change -23.86% -14.62% 32.44%
Gross Profit Margin 78.28% 68.84% 76.38%
Selling, General & Admin $4.740M $6.140M $6.520M
YoY Change -4.78% 49.07% 6.54%
% of Gross Profit 108.72% 136.14% 91.0%
Research & Development $1.880M $2.211M $2.520M
YoY Change -12.11% 3.95% 25.37%
% of Gross Profit 43.12% 49.02% 35.17%
Depreciation & Amortization $140.0K $70.00K $180.0K
YoY Change -12.5% 1.45% 5.88%
% of Gross Profit 3.21% 1.55% 2.51%
Operating Expenses $6.670M $8.403M $9.110M
YoY Change -7.15% 33.04% 10.96%
Operating Profit -$2.310M -$3.893M -$1.945M
YoY Change 58.44% 276.5% -30.54%
Interest Expense -$80.00K $130.0K -$1.390M
YoY Change -139.6% -37.8% 152.73%
% of Operating Profit
Other Income/Expense, Net -$7.893M
YoY Change 195.07%
Pretax Income -$2.390M -$11.79M -$3.340M
YoY Change -31.93% 217.77% -0.3%
Income Tax $10.00K $26.00K $10.00K
% Of Pretax Income
Net Earnings -$2.400M -$11.81M -$3.348M
YoY Change -32.01% 217.78% 0.12%
Net Earnings / Revenue -43.09% -180.31% -35.69%
Basic Earnings Per Share -$0.59
Diluted Earnings Per Share -$107.1K -$0.59 -$172.9K
COMMON SHARES
Basic Shares Outstanding 22.85M 20.18M 19.36M
Diluted Shares Outstanding 20.18M

Balance Sheet

Concept 2020 Q2 2020 Q1 2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $24.23M $14.26M $15.31M
YoY Change 23.81% 25.97% 25.59%
Cash & Equivalents $24.23M $14.26M $15.31M
Short-Term Investments
Other Short-Term Assets $1.430M $1.480M $1.440M
YoY Change 32.41% 7.25% 39.81%
Inventory $3.350M $2.462M $2.611M
Prepaid Expenses
Receivables $6.680M $7.090M $9.819M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $35.68M $25.31M $29.20M
YoY Change 19.86% 14.59% 37.59%
LONG-TERM ASSETS
Property, Plant & Equipment $2.720M $636.0K $551.0K
YoY Change 398.17% 24.46% -0.18%
Goodwill $8.362M $8.362M
YoY Change 0.0% 0.0%
Intangibles $1.107M $1.183M
YoY Change -23.97% -23.68%
Long-Term Investments
YoY Change
Other Assets $110.0K $90.00K $12.00M
YoY Change 120.0% 80.0% 20.43%
Total Long-Term Assets $12.23M $12.52M $12.55M
YoY Change 12.41% 12.66% 19.35%
TOTAL ASSETS
Total Short-Term Assets $35.68M $25.31M $29.20M
Total Long-Term Assets $12.23M $12.52M $12.55M
Total Assets $47.91M $37.83M $41.75M
YoY Change 17.87% 13.94% 31.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.420M $1.674M $1.990M
YoY Change -17.78% 12.8% 72.44%
Accrued Expenses $5.890M $6.100M $6.590M
YoY Change 4.8% -1.77% 30.24%
Deferred Revenue $5.604M
YoY Change 7.58%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $10.00K $4.260M
YoY Change -100.0% -99.56% 127.81%
Total Short-Term Liabilities $12.79M $13.84M $18.84M
YoY Change -13.9% -8.09% 42.21%
LONG-TERM LIABILITIES
Long-Term Debt $6.940M $6.960M $15.65M
YoY Change -52.3% -47.27% 39.23%
Other Long-Term Liabilities $1.700M $1.940M $2.190M
YoY Change 385.71% 424.32% 8011.11%
Total Long-Term Liabilities $8.640M $8.900M $17.84M
YoY Change -42.01% -34.41% 65974.07%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.79M $13.84M $18.84M
Total Long-Term Liabilities $8.640M $8.900M $17.84M
Total Liabilities $21.42M $22.74M $36.68M
YoY Change -28.0% -20.57% 47.65%
SHAREHOLDERS EQUITY
Retained Earnings -$236.1M -$224.3M
YoY Change 10.09% 6.43%
Common Stock $252.6M $230.8M
YoY Change 14.59% 5.35%
Preferred Stock
YoY Change
Treasury Stock (at cost) $1.415M $1.415M
YoY Change 0.0% 0.0%
Treasury Stock Shares $185.8K $185.8K
Shareholders Equity $26.49M $15.08M $5.071M
YoY Change
Total Liabilities & Shareholders Equity $47.91M $37.83M $41.75M
YoY Change 17.87% 13.94% 31.54%

Cashflow Statement

Concept 2020 Q2 2020 Q1 2019 Q4
OPERATING ACTIVITIES
Net Income -$2.400M -$11.81M -$3.348M
YoY Change -32.01% 217.78% 0.12%
Depreciation, Depletion And Amortization $140.0K $70.00K $180.0K
YoY Change -12.5% 1.45% 5.88%
Cash From Operating Activities -$2.150M -$1.416M -$2.340M
YoY Change 264.41% -21.9% 50.97%
INVESTING ACTIVITIES
Capital Expenditures -$30.00K $155.0K -$90.00K
YoY Change -72.73% 453.57% -55.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$30.00K -$156.0K -$90.00K
YoY Change -72.73% 437.93% -55.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 12.15M 515.0K 310.0K
YoY Change 35.6% -47.02% -95.65%
NET CHANGE
Cash From Operating Activities -2.150M -1.416M -2.340M
Cash From Investing Activities -30.00K -156.0K -90.00K
Cash From Financing Activities 12.15M 515.0K 310.0K
Net Change In Cash 9.970M -1.057M -2.120M
YoY Change 20.7% 21.49% -139.48%
FREE CASH FLOW
Cash From Operating Activities -$2.150M -$1.416M -$2.340M
Capital Expenditures -$30.00K $155.0K -$90.00K
Free Cash Flow -$2.120M -$1.571M -$2.250M
YoY Change 341.67% -14.67% 66.67%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1990000
CY2020Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6100000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6590000
CY2020Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2322000
CY2020Q1 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
93000
CY2019Q4 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
50000
CY2020Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1107000
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1183000
CY2020Q1 us-gaap Goodwill
Goodwill
8362000
CY2019Q4 us-gaap Notes Payable Current
NotesPayableCurrent
4250000
CY2020Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
5259000
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14256000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15313000
CY2020Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
7090000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
9819000
CY2020Q1 us-gaap Inventory Net
InventoryNet
2462000
CY2019Q4 us-gaap Inventory Net
InventoryNet
2611000
CY2020Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1497000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1453000
CY2020Q1 us-gaap Assets Current
AssetsCurrent
25305000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
29196000
CY2020Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1674000
CY2019Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
5248000
CY2020Q1 us-gaap Liabilities Current
LiabilitiesCurrent
13842000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
18836000
CY2019Q4 us-gaap Goodwill
Goodwill
8362000
CY2020Q1 us-gaap Assets
Assets
37825000
CY2020Q1 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
1707000
CY2019Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
1837000
CY2019Q4 us-gaap Assets
Assets
41748000
CY2020Q1 us-gaap Long Term Notes Payable
LongTermNotesPayable
6957000
CY2019Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
2003000
CY2019Q4 icad Convertible Debentures Payable To Non Related Parties At Fair Value
ConvertibleDebenturesPayableToNonRelatedPartiesAtFairValue
12409000
CY2019Q4 icad Convertible Debentures Payable To Related Parties At Fair Value
ConvertibleDebenturesPayableToRelatedPartiesAtFairValue
1233000
CY2020Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
232000
CY2019Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
356000
CY2020Q1 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
4000
CY2019Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
3000
CY2020Q1 us-gaap Liabilities
Liabilities
22742000
CY2019Q4 us-gaap Liabilities
Liabilities
36677000
CY2020Q1 us-gaap Common Stock Value
CommonStockValue
215000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
195000
CY2020Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
252419000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
230615000
CY2020Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-236136000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-224324000
CY2020Q1 us-gaap Treasury Stock Value
TreasuryStockValue
1415000
CY2019Q4 us-gaap Treasury Stock Value
TreasuryStockValue
1415000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
15083000
CY2020Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
37825000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
41748000
CY2020Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q1 icad Lease Liability Current
LeaseLiabilityCurrent
809000
CY2019Q4 icad Lease Liability Current
LeaseLiabilityCurrent
758000
CY2020Q1 us-gaap Cost Of Goods And Services Sold Depreciation And Amortization
CostOfGoodsAndServicesSoldDepreciationAndAmortization
97000
CY2019Q1 us-gaap Cost Of Goods And Services Sold Depreciation And Amortization
CostOfGoodsAndServicesSoldDepreciationAndAmortization
94000
CY2020Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2041000
CY2019Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1491000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2211000
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2127000
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.59
CY2019Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.59
CY2019Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
CY2020Q1 us-gaap Gross Profit
GrossProfit
4510000
CY2019Q1 us-gaap Gross Profit
GrossProfit
5282000
CY2020Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3608000
CY2019Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2573000
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2532000
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1546000
CY2020Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
6551000
CY2019Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
6773000
CY2020Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
52000
CY2019Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
70000
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
8403000
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
6316000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3893000
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1034000
CY2020Q1 us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
7464000
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-7893000
CY2019Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2675000
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11786000
CY2019Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3709000
CY2020Q1 us-gaap Adjustment For Amortization
AdjustmentForAmortization
79000
CY2019Q1 us-gaap Adjustment For Amortization
AdjustmentForAmortization
95000
CY2020Q1 us-gaap Depreciation
Depreciation
70000
CY2019Q1 us-gaap Depreciation
Depreciation
69000
CY2020Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
119000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
464000
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
212000
CY2020Q1 icad Amortization Accretion Of Discounts And Premiums
AmortizationAccretionOfDiscountsAndPremiums
40000
CY2019Q1 icad Amortization Accretion Of Discounts And Premiums
AmortizationAccretionOfDiscountsAndPremiums
39000
CY2020Q1 icad Change In Fair Value Of Convertible Debentures
ChangeInFairValueOfConvertibleDebentures
7464000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-317000
CY2019Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1175000
CY2019Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
330000
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-439000
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2610000
CY2019Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
984000
CY2020Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-149000
CY2019Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
403000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
72000
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
347000
CY2019Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
414000
CY2020Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-113000
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
21164000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
5071000
CY2020Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
196000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
464000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
4566000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
6896000
CY2019Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1175000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
212000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-11812000
CY2019Q1 us-gaap Profit Loss
ProfitLoss
-3717000
CY2019Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-46000
CY2020Q1 us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
10396000
CY2019Q1 us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
1904000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1416000
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1813000
CY2020Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
1000
CY2019Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
1000
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
155000
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
28000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-156000
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-29000
CY2020Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
196000
CY2019Q1 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
3000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
515000
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
972000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1057000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-870000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15313000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12185000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14256000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11315000
CY2020Q1 us-gaap Interest Paid Net
InterestPaidNet
122000
CY2019Q1 us-gaap Interest Paid Net
InterestPaidNet
82000
CY2020Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
26000
CY2019Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
8000
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6551000
CY2020Q1 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
1000
CY2020Q1 us-gaap Proceeds From Repayments Of Secured Debt
ProceedsFromRepaymentsOfSecuredDebt
-4638000
CY2020Q1 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
2000000
CY2020Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
69000
CY2020Q1 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
21164000
CY2019Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6773000
CY2019Q4 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
13642000
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
136000
CY2019Q1 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
21164000
CY2020Q1 us-gaap Accounts Receivable Net
AccountsReceivableNet
7090000
CY2020Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
5491000
CY2019Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
5604000
CY2020Q1 icad Deferral Of Revenue
DeferralOfRevenue
2226000
CY2020Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-2339000
CY2019Q4 us-gaap Convertible Debt
ConvertibleDebt
6970000
CY2019Q1 us-gaap Convertible Debt
ConvertibleDebt
6970000
CY2019Q1 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
82000
CY2020Q1 icad Interest Expense Convertible Debentures
InterestExpenseConvertibleDebentures
49000
CY2019Q1 icad Interest Expense Convertible Debentures
InterestExpenseConvertibleDebentures
87000
CY2020Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
7000
CY2019Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
7000
CY2020Q1 icad Accrued Amount Of Final Payment Of Term Loan
AccruedAmountOfFinalPaymentOfTermLoan
31000
CY2019Q1 icad Accrued Amount Of Final Payment Of Term Loan
AccruedAmountOfFinalPaymentOfTermLoan
32000
CY2019Q1 us-gaap Interest Expense Lessee Assets Under Capital Lease
InterestExpenseLesseeAssetsUnderCapitalLease
1000
CY2020Q1 us-gaap Interest Expense
InterestExpense
130000
CY2019Q1 us-gaap Interest Expense
InterestExpense
209000
CY2020Q1 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
43000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
464000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
212000
CY2020Q1 icad Segment Operating Income Loss
SegmentOperatingIncomeLoss
-1352000
CY2019Q1 icad Segment Operating Income Loss
SegmentOperatingIncomeLoss
523000
CY2020Q1 icad General Administrative Depreciation And Amortization Expense
GeneralAdministrativeDepreciationAndAmortizationExpense
2541000
CY2019Q1 icad General Administrative Depreciation And Amortization Expense
GeneralAdministrativeDepreciationAndAmortizationExpense
1557000
CY2020Q1 us-gaap Interest Expense
InterestExpense
130000
CY2019Q1 us-gaap Interest Expense
InterestExpense
209000
CY2020Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
42000
CY2019Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
59000
CY2020Q1 us-gaap Purchase Obligation
PurchaseObligation
5900000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2406000
CY2020Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
255000
CY2020Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6580000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6510000
CY2020Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
8263000
CY2019Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
8186000
CY2020Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2020Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
30000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
30000000
CY2020Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21425916
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19546151
CY2020Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21240085
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19360320
CY2020Q1 us-gaap Treasury Stock Shares
TreasuryStockShares
185831
CY2019Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
185831
CY2019Q1 us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
2525000
CY2020Q1 icad Deferred Revenue To Be Recognized There After
DeferredRevenueToBeRecognizedThereAfter
200000
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3561382
CY2020Q1 icad Deferred Revenue To Be Recognized In Next Twelve Months
DeferredRevenueToBeRecognizedInNextTwelveMonths
4800000
CY2020Q1 icad Deferred Revenue To Be Recognized Year Two
DeferredRevenueToBeRecognizedYearTwo
500000
CY2019Q1 icad Change In Fair Value Of Convertible Debentures
ChangeInFairValueOfConvertibleDebentures
2525000
CY2019Q1 us-gaap Proceeds From Repayments Of Secured Debt
ProceedsFromRepaymentsOfSecuredDebt
-200000
CY2019Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
907000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-11812000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-3717000
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20175000
CY2019Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17200000
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20175000
CY2019Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
17200000
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.59
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.22
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1821855
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
547000
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
1396000
CY2020Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q1 us-gaap Debt Instrument Redemption Description
DebtInstrumentRedemptionDescription
The simulation utilized the assumptions that if the Company is able to exercise its Forced Conversion right (if the requirements to do so are met), that it will do so in 100% of such scenarios. Additionally, if an event of default occurs during the simulated trial (based on the Company’s probability of default), the Investors will opt to redeem the Convertible Debentures in 100% of such scenarios
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
692000
CY2020Q1 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
9000
CY2020Q1 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
701000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
920000
CY2020Q1 us-gaap Contractual Obligation Due In Second Year
ContractualObligationDueInSecondYear
920000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
899000
CY2020Q1 us-gaap Contractual Obligation Due In Third Year
ContractualObligationDueInThirdYear
899000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
211000
CY2020Q1 us-gaap Contractual Obligation Due In Fourth Year
ContractualObligationDueInFourthYear
211000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
5000
CY2020Q1 us-gaap Contractual Obligation Due In Fifth Year
ContractualObligationDueInFifthYear
5000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2727000
CY2020Q1 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
9000
CY2020Q1 us-gaap Contractual Obligation
ContractualObligation
2736000
CY2020Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
219000
CY2020Q1 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
1000
CY2020Q1 icad Lease Liability Undiscounted Excess Amount
LeaseLiabilityUndiscountedExcessAmount
-220000
CY2020Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
2508000
CY2020Q1 us-gaap Finance Lease Liability
FinanceLeaseLiability
8000
CY2020Q1 icad Lease Liability Payments Due
LeaseLiabilityPaymentsDue
2516000
CY2020Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
801000
CY2020Q1 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
8000
CY2020Q1 icad Lease Liability Current
LeaseLiabilityCurrent
809000
CY2020Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1707000
CY2020Q1 icad Lease Liability Non Current
LeaseLiabilityNonCurrent
1707000
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
4749000
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2273000
CY2020Q1 dei Document Period End Date
DocumentPeriodEndDate
2020-03-31
CY2020Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2020Q1 dei Entity Registrant Name
EntityRegistrantName
ICAD INC
CY2020Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000749660
CY2020Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2020Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2019Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
15313000
CY2019Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
13642000
CY2020Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
14256000
CY2020Q1 dei Document Type
DocumentType
10-Q
CY2020Q1 dei Amendment Flag
AmendmentFlag
false
CY2020Q1 dei Trading Symbol
TradingSymbol
ICAD
CY2020Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2020Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2020Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NH
CY2020Q1 dei Entity Shell Company
EntityShellCompany
false
CY2020Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q1 dei Security12b Title
Security12bTitle
Common Stock
CY2020Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
636000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
551000
CY2018Q4 us-gaap Goodwill Gross
GoodwillGross
47937000
CY2018Q4 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
26828000
CY2018 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
116000
CY2018 us-gaap Goodwill Written Off Related To Sale Of Business Unit
GoodwillWrittenOffRelatedToSaleOfBusinessUnit
394000
CY2018 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
19716000
CY2018Q4 us-gaap Goodwill
Goodwill
8362000
CY2020Q1 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill
4000
CY2020Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued
0
CY2020Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1632000
CY2020Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
14000
CY2020Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
43000
CY2020Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1469000
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q1 us-gaap Inventory Gross
InventoryGross
2746000
CY2020Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-341000
CY2020Q1 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
7000000
CY2020Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-341000
CY2020Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Risk and Uncertainty </div></div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;12, 2020, the World Health Organization declared <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> to be a pandemic. In an effort to contain and mitigate the spread of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> many countries, including the United States, Canada and China, have imposed unprecedented restrictions on travel, and there have been business closures and a substantial reduction in economic activity in countries that have had significant outbreaks of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> As a provider of devices and services to the health care industry, our operations have been materially affected. Significant uncertainty remains as to the potential impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic on our continuing operations and on the global economy as a whole. It is currently not possible to predict how long the pandemic will last or the time that it will take for economic activity to return to prior levels. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic has resulted in significant financial market volatility and uncertainty. A continuation or worsening of the levels of market disruption and volatility seen in the recent past could have an adverse effect on our ability to access capital, on our business, results of operations and financial condition, and on the market price of our common stock. Accessing capital may be impacted by the fact that there is a minimum revenue covenant contained in the Company&#8217;s Loan and Security Agreement with Western Alliance Bank (see note 4 (b) for details) that could be impacted by the COVID 19 pandemic. If at any point the Company is not in compliance with such covenant and is unable to obtain an amendment or waiver, such noncompliance may result in an event of default under the Loan and Security Agreement, which could result in acceleration of the outstanding indebtedness and require the Company to repay such indebtedness before the scheduled due date. </div> <div style="color: rgb(0, 0, 0); font-family: &quot;times new roman&quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: 0px; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">The Company believes even if that event of default were to occur, the Company&#8217;s current liquidity and capital resources are sufficient to sustain operations through at least the next 12 months, primarily due to cash on hand, which now includes an additional estimated $12.2 million the Company received following the sale of 1,562,500 shares of the Company&#8217;s common stock at $8.00 per share, pursuant to a registered direct offering which closed on April 27, 2020.</div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="color: rgb(0, 0, 0); font-family: &quot;times new roman&quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: 0px; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">Our results for the quarter ending March&#160;31, 2020 reflect a negative impact from, among other things, the&#160;</div><div style="color: rgb(0, 0, 0); font-family: &quot;times new roman&quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: 0px; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; white-space: nowrap; top: 0px;;display:inline;">COVID-19</div><div style="font-size: 13.3333px; color: rgb(0, 0, 0); font-family: &quot;times new roman&quot;; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: 0px; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">&#160;pandemic as shipping, logistics, acceptance and installation and training have been delayed and ordering patterns disrupted. Although we do not provide guidance to investors relating to our future results of operations, we expect that our results for the quarter ending June&#160;30, 2020, and possibly future quarters, will reflect a negative impact from the&#160;</div><div style="color: rgb(0, 0, 0); font-family: &quot;times new roman&quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: 0px; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; white-space: nowrap; top: 0px;;display:inline;">COVID-19</div><div style="color: rgb(0, 0, 0); font-family: &quot;times new roman&quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: 0px; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">&#160;pandemic for similar reasons. Depending upon the duration and severity of the pandemic, the continuing effect on our results over the long term is uncertain.</div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s exposure to trade accounts receivable losses may increase if its customers are adversely affected by changes in healthcare laws, coverage, and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the current <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, or other customer-specific factors. Although the Company has historically not experienced significant trade account receivable losses, it is possible that there could be a material adverse impact from potential adjustments of the carrying amount of trade account receivables as hospitals&#8217; cash flows are impacted by their response to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2020Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1502000
CY2019Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1572000
CY2020Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
97000
CY2019Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
39000
CY2020Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1147000
CY2019Q4 us-gaap Inventory Gross
InventoryGross
3080000
CY2020Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
284000
CY2019Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
469000
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
26000
CY2019Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
8000
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
26000
CY2019Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
8000
CY2020Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
22853545
CY2020Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
151000
CY2020Q1 icad Final Payment Of Loan
FinalPaymentOfLoan
510000
CY2020Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2020Q1 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
14000
CY2019Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
14000
CY2020Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
0
CY2020Q1 us-gaap Gain Loss On Sales Of Loans Net
GainLossOnSalesOfLoansNet
7500000

Files In Submission

Name View Source Status
0001193125-20-139218-index-headers.html Edgar Link pending
0001193125-20-139218-index.html Edgar Link pending
0001193125-20-139218.txt Edgar Link pending
0001193125-20-139218-xbrl.zip Edgar Link pending
d916347d10q.htm Edgar Link pending
d916347dex311.htm Edgar Link pending
d916347dex312.htm Edgar Link pending
d916347dex321.htm Edgar Link pending
d916347dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
icad-20200331.xml Edgar Link completed
icad-20200331.xsd Edgar Link pending
icad-20200331_cal.xml Edgar Link unprocessable
icad-20200331_def.xml Edgar Link unprocessable
icad-20200331_lab.xml Edgar Link unprocessable
icad-20200331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending